| abstract |
The compounds are suitable, for example, as antiarrhythmic drugs, with a cardioprotective component for the prophylaxis of infarction and treatment of infarction, and for the treatment of angina pectoris. They also inhibit in a preventive way the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of arrhythmias. Claim 1: Compounds of the formula (1) wherein R1 is H or C1-6 alkyl; R2 is H, C1-6 alkyl, halogen, NRaRb or C1-4 polyfluoroalkyl, Ra and Rb are independently from each other, H, C1-6 alkyl, linear or branched, or Ra and Rb form, together with the N-atom which are attached, a 5- or 6-membered heterocycle, which may optionally contain another heteroatom chosen from O, S, and N; R3 is H, C1-6 alkyl, halogen, C1-6 alkoxy or hydroxyl; R4 is H, C1-6 alkyl, halogen, C1-6 alkoxy or hydroxyl; R5 is H or halogen; Ar is a 9 or 10-membered bicyclic heteroaryl having one, two or three N atoms, which may be linked by any of its positions, and its racemic mixtures, enantiomers and diastereoisomers, and mixtures thereof, their tautomers and their pharmaceutically active salts. acceptable. |